MimiVax Announces New Investments to Support Clinical Development of SurVaxM in Glioblastoma
Example of a transitional model for financing brain cancer therapeutics development
Congratulations to MimiVax and the investors, many of whom are colleagues and thought partners with MissionGBM! We would particularly like to highlight the integrity, scientific acumen and perseverance of the company CEO Michael Ciesielski, PhD. We have met with Dr. Ciesielski, and he always comes prepared with data, thoughtful plans and an open mind, which exemplifies the credibility that is required to attract investment capital to evidence-based healthcare ventures.
We also wanted to highlight the MimiVax financing because it is an example of one model for brain cancer investment that we believe will be critical to bridging the gap between early stage research findings and the translational clinical science that will be needed to attract significant institutional capital (i.e. > $30 million).
Stay tuned for upcoming posts about Investing in Brain Cancer in which we will examine the key issues in detail, and propose a few paths forward.